CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 245 enrolled
Drug / intervention
escitalopram +2 moredrug
Likely dose
escitalopram 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00519428
NCT00519428Phase 4Completed
CompareCT.gov

Combining Antidepressants to Hasten Remission From Depression

New York State Psychiatric Institute·interventional·Posted Aug 22, 2007·Updated Oct 4, 2017

In Brief

A Phase 4 clinical trial evaluating escitalopram, bupropion extra long (XL), and 1 other intervention for Major Depressive Disorder. Completed, enrolled 245 participants across 2 sites in 2 countries.

Detailed Summary

This study will utilize a randomized double-blind design to evaluate whether initial treatment with two anti-depressant medications (escitalopram and bupropion) results in more rapid remission and greater over-all remission rates than either monotherapy in 240 depressed subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesCanada, United States
CollaboratorsUniversity of Ottawa, National Institute of Mental Health (NIMH)

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 22, 2007
Enrollment StartAug 1, 2007
Primary CompletionJul 1, 2011
Study CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 18.9 years ago

Interventions

escitalopramdrug

10mg/d increasing by 10 mg/week to a maximum of 40 mg/d if tolerated and not remitted

bupropion extra long (XL)drug

150mg/d increasing to 300 mg/d after 1 week and 450 mg/d after 3 weeks, all increases if tolerated and not remitted

escitalopram + bupropiondrug

same dosing schedule as for monotherapy